By Dr. Chinta SidharthanFeb 8 2023Reviewed by Danielle Ellis, B.Sc. In a recent study published in the Journal of Clinical Medicine, researchers investigated the B cell and humoral immune responses elicited against inactivated and recombinant severe acute respiratory syndrome coronavirus 2 vaccines, and their safety profiles in patients with chronic kidney disease .
Since memory B-cell responses to SARS-CoV-2 have not been extensively studied, the duration of protection against COVID-19 granted by these vaccines among patients with CKD is not clearly understood. Furthermore, the efficacy and safety of inactivated and recombinant SARS-CoV-2 vaccines, widely used worldwide, have not been studied among CKD patients.
Online questionnaires were administered to all participants to gather data on patient demographics, clinical data, and adverse events, including age, sex, the time between vaccination and sample collection, comorbidities, type of vaccine, and body mass index. Plasma samples were obtained to measure the immunoglobulin G antibodies against the SARS-CoV-2 spike protein receptor binding domain . Chemiluminescence immunoassays were used to detect the anti-RBD IgG and neutralizing antibody levels.
However, in the subgroup analysis involving CKD patients undergoing hemodialysis, the positivity rates for the anti-RBD IgG levels were significantly lower than that of the control group. Furthermore, when the neutralizing antibody levels were analyzed further, the patients with CKD and those requiring hemodialysis had lower neutralizing antibody levels.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NewsMedical - 🏆 19. / 71 Read more »